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Introduction: Few prospective studies have examined mortality outcomes associated with 
smokeless tobacco use in the US and information is limited regarding the risks associated with 
former and current exclusive smokeless tobacco users compared to combustible tobacco smoking 
and dual use. 
Objective: To investigate associations of smoking and smokeless tobacco use with all-cause, 
cancer, cardiovascular disease, and chronic lower respiratory disease mortality in US adults. 
Methods: We studied 127,995 adults, 18 years of age or older, who participated in the National 
Health Interview Survey 1987, 1992, 1998, 2000 and 2005 Cancer Control Supplement and were 
followed for mortality through December 2011. Information on history of combustible tobacco  
(cigarettes, pipes or cigars) smoking and smokeless tobacco (SLT: chewing tobacco or snuff) use 
was assessed at baseline. Cox proportional hazards models were used to estimate hazard ratios 
(HR) and 95% confidence intervals (CI) for mortality outcomes comparing former and current 
SLT users, former and current smokers and current dual users to never tobacco users. 
Results: 51% of participants were never tobacco users, 1% former SLT users, 1% current SLT 
users, 22% former smokers, 25% current smokers and 1% current dual users. After a median 
follow-up time of 12 years, there were 23,405 deaths. After multivariable adjustment, the risk for 
all-cause mortality was higher for combustible tobacco users compared to never users (HR [95% 
CI] were 1.29 [1.25-1.34], 1.85 [1.78-1.93] and 1.69 [1.48-1.94] for former smokers, current 
smokers and current dual users respectively). The risk for death during follow-up time for 
exclusive SLT users was not significantly different from never users (HR [95% CI]: 0.93 [0.76-
1.14] for former SLT users and 0.95 [0.80-1.12] for current SLT users).  
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Conclusions: Compared to never tobacco users, combustible tobacco users had higher risk in all-
cause, cancer, cardiovascular disease, and chronic lower respiratory disease mortality. Exclusive 
smokeless tobacco users did not have higher risk than never tobacco users. These results suggest 
that using smokeless tobacco as a replacement for combustible tobacco smoking may reduce 
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INTRODUCTION   
 
Mortality due to cigarette smoking is estimated to rise to 7.2 million worldwide in 2017.1 
In the United States, the Centers for Disease Control and Prevention (CDC) estimated 480,000 
deaths annually were related to cigarette smoking.2 Cigarette smoking has been associated with 
several cancers including lung, head and neck, kidney, bladder, liver, pancreas, stomach, cervix, 
colon, and rectum and is also a major risk factor of cardiovascular diseases.3 Even though the 
prevalence of cigarette smoking has greatly declined since the 1980s, data from CDC indicates 
that 15.1% of U.S. adults were cigarette smokers in 2015.4 Reducing cigarette smoking among 
U.S. population has always been the major task for tobacco control and intervention.3 As a 
British nicotine researcher Dr. Russell had suggested in his 1976 British Medical Journal article, 
“People smoke for nicotine but they die from the tar”5 thus the use of combustible tobacco 
products which yield tar, should be minimized. Smokeless tobacco (SLT) products such as 
chewing tobacco on the other hand does not produce combustion gases and particles,6  however, 
smokeless tobacco still contains carcinogenic tobacco-specific nitrosamines.6,7 Few studies have 
examined smokeless tobacco products with mortality outcomes in the United States8-11 with two 
studies finding no association between SLT use and all-cause mortality or death from cancer and 
cardiovascular8-9 and two studies showing that SLT use may be associated with higher mortality 
due to cardiovascular diseases but no difference for cancer mortality.10,11 A study using data 
from the First National Health and Nutrition Examination Survey Epidemiologic Followup Study 
found no difference in all-cause, cancer, or cardiovascular disease mortality for SLT users 
compared to non-tobacco users, except for some evidence of an increase in cancer mortality 
among female smokeless tobacco users.9 However, this study was limited by examining ever use 
of smokeless tobacco (combined current and former user) and was not able to account for use of 
2 
 
other combustible non-cigarette tobacco products (e.g., cigars and pipes). A prospective study 
using data from the Cancer Prevention Study (CPS) I, which enrolled participants in 1959 
(followed for 12 years), and CPS II, which enrolled participants in 1982 (followed for 18 years), 
showed significant higher all-cause and cardiovascular disease mortality for men who reported 
exclusive current smokeless tobacco use compared to never tobacco users.10 Though, this study 
excluded men who reported current or former smoking of cigarettes, cigars, or pipes and no 
information was available on the use of chewing tobacco or snuff by women. Therefore, the 
objective of our study was to investigate associations of former and current SLT and combustible 
tobacco use compared to never tobacco use with all-cause, cancer, cardiovascular and respiratory 
mortality in a representative sample of US adults in the National Health Interview Survey 
(NHIS). The availability of information on current and past use of both SLT and cigarette and 
non-cigarette combustible products in NHIS allowed us to examine the health risk from use of 






The National Health Interview Survey (NHIS) is a nationwide in-person annual survey of 
approximately 35,000 households in the civilian non-institutionalized U.S. population conducted 
by the U.S. National Center for Health Statistics (NCHS; Centers for Disease Control and 
Prevention [CDC], Atlanta, GA) since 1957.12 Since 1987, the National Cancer Institute 
periodically sponsors a Cancer Control Supplement (CCS) to the NHIS to focus on issues related 
to cancer-related health behaviors, screening, and risk assessment.13 In the years of 1987, 1992, 
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1998, 2000 and 2005, one adult aged 18 or older per household was randomly selected for CCS 
interview with informed consent. In NHIS 1987 and 1992, African Americans were over 
sampled and in NHIS 1998, 2000, and 2005, African American and Hispanic subpopulations 
were over sampled to allow for more precise estimates in these groups. We aggregated the CCS 
data sets that linked to the National Death Index14 to form the study population of 147,023 adults 
eligible for mortality follow-up and whose mortality status were ascertained. We excluded 5,735 
adults whose tobacco use information was missing, 6,077 dual combustible and smokeless 
tobacco users who had quit SLT use or smoking by baseline, and 7,216 adults missing covariates 
of interest. The final sample size for this analysis was 127,995 adults.  
Mortality Follow-up 
 
Participants were followed for mortality from the date of survey participation (1987, 1991-1992, 
1998, 2000 or 2005) through December 31, 2011. Vital status and cause of death were 
ascertained through probabilistic record matching between NHIS records and death certificates 
from the National Death Index.14 The cause of death was determined using the underlying cause 
listed on death certificates, and coded using the International Classification of Diseases, 10th 
Revision (ICD-10). The primary outcome was all-cause mortality. Secondary outcomes were 
death from cancer (ICD-10 codes: C00-C97), cardiovascular diseases (CVD, ICD-10 codes: I00-
I09, I11, I13, I20-I51, I60-I69) and chronic lower respiratory disease (CLRD, ICD-10 codes: 
J40-J47). Follow-up time for each participant was calculated as the difference between the age at 
the time of the NHIS interview and the age at the date of death, age 100 years or end of the 
mortality follow-up period (December 31, 2011), whichever occurred first.  Follow-up was 
censored at age 100 years because the age was top-coded at 99 years and the probabilistic nature 
of the mortality ascertainment, the lower likelihood of being alive at 100 years or older. 
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 Tobacco Use  
 
Information on participant tobacco use was obtained from a self-reported questionnaire and 
defined based on history of use of combustible and tobacco products. Smokers were defined by 
history of use of combustible tobacco products including cigarettes, pipes and cigars. Those who 
ever smoked at least 100 cigarettes, 50 cigars, 50 times of pipes were considered ever smokers; 
those who answer “no” were classified as never smokers. Ever smokers who responded to the 
question: “Do you now smoke cigarettes/a cigar/a pipe everyday, some days, or not at all?” with 
“everyday” or “some days” were classified as current smokers; ever smokers who responded 
“not at all” were classified as former smokers. For participants who reported a history of 
cigarette smoking, information was obtained on the number of cigarettes smoked each day for 
“everyday” current smokers and average cigarettes smoked per day in the past 30 days for “some 
days” current smokers. SLT use was defined by history of use of chewing tobacco or snuff. 
Those who ever used chewing tobacco or snuff at least 20 times were considered ever SLT users; 
those who answer “no” were classified as never SLT users. Ever SLT users who responded to the 
question: “Do you now use chewing tobacco/snuff everyday, some days, or not at all?” with 
“everyday” or “some days” were classified as current SLT users; SLT users who responded “not 
at all” were classified as former SLT users. For year 1987, the current “everyday” and “some 
days” smokers or SLT users were not distinguished. The questions for 1987 NHIS were “Do you 
smoke/use cigarettes/a pipe/a cigar/chewing tobacco/snuff now?” Participants who were both 
never smokers and never SLT users were classified as never tobacco users ( “Never Users”). For 
this analysis, tobacco use was categorized as former SLT use only ("Former SLT Users”) who 
were former SLT users and never smokers, current SLT use only (“Current SLT Users”) who 
were current SLT users and never smokers, former smokers only ( “Former Smokers”) who were 
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former smokers and never SLT users, current smokers only (“Current Smokers”) who were 
current smokers and never SLT users, and current dual users (“Current Dual Users”) who were 
current smokers and used SLT currently. 
Other Covariates 
 
Information on age, sex, body mass index (BMI), education level, family income, race/ethnicity 
and marital status were collected by questionnaire at the time of the interview (baseline). BMI 
was calculated by self-reported height and weight without shoes and treated as continuous 
variable. Education level was defined in four categories: less than high school, high school, some 
college, and college degree or beyond. Poverty-to-income ratio (PIR; the ratio of the family’s 
income to its appropriate poverty threshold as defined by the US Census Bureau) was 
dichotomized as PIR <1.00 vs. ≥1.00. Race/ethnicity was defined as Hispanic, Non-Hispanic 
white, Non-Hispanic black and non-Hispanic other. Marital status was categorized as married 
with or without spouse living together or living together with partner vs. all others. Year of NHIS 
interview (1987, 1992, 1998, 2002 and 2005) was also included in the model and treated as a 
categorical variable to account for secular trends.  
Statistical Analysis 
 
We estimated multivariable adjusted hazard ratios (HR) and 95% confidence intervals (CI) for 
primary and secondary mortality outcomes comparing Former SLT Users, Current SLT Users, 
Former Smokers, Current Smokers and Dual Users to Never Users using Cox proportional 
hazards models with age as the time scale and individual starting follow-up times (age at 
interview) treated as staggered entries. Models were adjusted for sex, race/ethnicity, education, 
marital status, PIR, BMI and year of survey.  Type 1 error rate was set at 0.05 level. All 
statistical analyses were performed using the “svy” package in STATA 14.2 (StataCorp. 2015. 
6 
 
Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) to account for the 






Table 1 shows the characteristics of study participants at baseline. Of the 127,995 adults included 
in this analysis, a little more than half of them (weighted prevalence: 51%) were Never Users 
(Table 1). Former Smokers and Current Smokers made up nearly the other half (25% and 21% 
respectively). Those who exclusively used smokeless tobacco (Former SLT and Current SLT) 
and Current Dual Users were each about one percent of the study population. Compared to Never 
Users, smokeless tobacco users including Former SLT, Current SLT Current Dual Users were 
younger. Among exclusive smokers, Current Smokers were somewhat younger (42.4 years vs. 
44.4 years) and Former Smokers were about 10 years older than Never Users (Table 1). Those 
who ever used smokeless tobacco (Former SLT users, Current SLT users, and Current Dual 
Users) were mostly male (more than 85%) while Former Smokers and Current Smokers had 
approximately equal percentages of males and females and Never Users were about two thirds 
female (65%). Participants with a history of tobacco use (Former SLT Users, Current SLT Users, 
Former Smokers, Current Smokers and Current Dual Users) were more likely to be non-Hispanic 
white than Never Users (Table 1). Former SLT Users were more like to have some college 
education or beyond, while Current SLT Users, Current Smokers and Current Dual Users were 
more likely to have less than high school education. Marital status was similar across tobacco use 
categories except for a higher percentage of Former Smokers that reported being married or 
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living with a partner. Current tobacco users (Current SLT Users, Current Smokers and Current 
Dual Users) had higher percentages with household incomes below the poverty threshold while 
Former Smokers had the fewest. BMI was higher for Current SLT Users compared to all other 
groups (Table 1). For participants that reported current cigarettes smoking, cigarettes smoked per 
day was similar (mean cigarettes/day were 16.6 cigarettes for Current Smokers and 17.4 
cigarettes for Current Dual Users, Table 1).  
 Tobacco Use and Mortality Outcomes  
 
All-cause mortality. The median follow-up time was 12 years for the study population, 7.6 years 
for participants who were assumed deceased and 13.3 years for participants who were assumed 
alive at the end of follow-up. A total of 23,405 participants died during follow-up. After 
adjustment for age, sex, race/ethnicity, education, marital status, poverty level, BMI and year of 
survey, the risk for all-cause mortality was higher for combustible tobacco users compared to 
never users (HR [95% CI] were 1.29 [1.25-1.34], 1.85 [1.78-1.93] and 1.69 [1.48-1.94] for 
Former Smokers, Current Smokers and Current Dual Users respectively, Table 2). The risk for 
death during follow-up time for exclusive smokeless tobacco users was not significantly different 
from Never Users (HR [95% CI]: 0.93 [0.76-1.14] for Former SLT Users and 0.95 [0.80-1.12] 
for Current SLT Users, Table 2).  
Cancer mortality. There were 5,524 deaths due to any cancer. The multivariable adjusted risk for 
cancer mortality was higher for combustible tobacco users compared to never users (HR [95% 
CI] were 1.53 [1.42-1.64], 2.73 [2.52-2.95], 2.03 [1.52-2.71] for Former Smokers, Current 
Smokers and Current Dual Users respectively, Table 2). The risk of dying from cancer during 
follow-up time for exclusive smokeless tobacco users was not significantly different from Never 
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Users (HR [95% CI] were 0.71 [0.41-1.22], and 1.15 [0.80-1.63] for Former SLT Users and 
Current SLT Users respectively, Table 2).  
Cardiovascular disease mortality. There were 6,707 deaths due to CVD. The multivariable 
adjusted risk for CVD mortality was significantly higher for former and current smokers and 
significantly lower for current SLT users compared to never users (HR [95% CI] were 1.10 
[1.03-1.17] for Former Smokers, 1.56 [1.45-1.68] for Current Smokers and 0.70 [0.53-0.93] for 
Current SLT Users, Table 2). There was no difference in the risk of dying from CVD for former 
smokeless tobacco users or current dual users (HR [95% CI] were 0.84 [0.60-1.16] for Former 
SLT Users and 1.27 [0.94-1.72]  for Current Dual Users, Table 2).  
Chronic lower respiratory disease mortality. There were 1,297 deaths due to chronic lower 
respiratory disease. The multivariable adjusted risk for CLRD mortality was higher for 
combustible tobacco users compared to never users (HR [95% CI] were 5.25 [4.28-6.45], 10.08 
[8.17-12.43], 12.12 [7.57-19.41] for Former Smokers, Current Smokers and Current Dual Users 
respectively, Table 2). The risk of dying from CLRD during follow-up time for exclusive 
smokeless tobacco users was not significantly different from Never Users (HR [95% CI] were 
0.53 [0.07-3.85], and 1.04 [0.33-3.29] for Former SLT Users and Current SLT Users 
respectively, Table 2). 
DISCUSSION 
 
This study using nationally representative data of the US population, investigated the 
association between smokeless tobacco use and various mortality outcomes. Compared to 
participants who never used tobacco products, exclusive combustible tobacco smokers had 
statistically higher mortality risk while exclusive smokeless tobacco users did not show different 
mortality than never users. These findings were consistent among primary outcome (all-cause 
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mortality) and three different secondary endpoints (death from cancer, cardiovascular disease 
and chronicle lower respiratory disease). In addition to that, within the same category of tobacco 
products, either combustible or smokeless, participants who quit using tobacco experienced 
lower mortality risk compared to current users in all mortality outcomes. 
Mortality Outcomes among Exclusive Combustible Smokers vs. Exclusive SLT Users 
 
This study using US national representative data compared mortality between exclusive 
combustible smokers and exclusive smokeless tobacco users. Previous US studies have 
examined the mortality between exclusive SLT users with never users,9-11 or between SLT users 
vs non-users among former smokers.17  A systematic review of Swedish snus use among men 
found that SLT use was significantly associated with lower all-cause mortality than cigarette 
smokers.27 Among the exclusive smokers and exclusive smokeless tobacco users in this study, 
risks for all-cause, cancer, CVD and CLRD mortality were highest for the Current Smokers, 
followed by Former Smokers, then Current SLT Users and lowest for Former SLT Users, except 
for CVD mortality where Current SLT Users had lower risk than Former SLT Users, although 
these findings were not statistically significant (p=0.33, data not shown). The benefits of 
cigarette smoking cessation with reduced risk in all-cause mortality, death due to cancer and 
cardiovascular disease is well studied and widely accepted.3 In addition to lower risk for former 
cigarette smokers compared to current smokers, this study showed that quitting smokeless 
tobacco could also bring health benefits. Indeed, risk for mortality endpoints were lower for 
former SLT users than current SLT Users, except for a lower risk for CVD mortality for current 
SLT users.  




This study found that exclusive smokeless tobacco users had similar or lower mortality for all 
endpoints compared to never tobacco users. For all-cause mortality, a previous study using data 
from Tobacco Use Supplement of Current Population Survey (TUS-CPS) from year 1985 to 
2011 showed a similar result.11 Using data from the First National Health and Nutrition 
Examination Survey Epidemiologic Followup Study (adults aged ≥45 years at baseline [1971–
1975] followed for 20 years), there was similarly no difference in all-cause, cancer, or 
cardiovascular disease mortality for SLT users compared to non-tobacco users (defined as non-
users of SLT or cigarettes), except for some evidence of an increase in cancer mortality among 
female smokeless tobacco users.9 Another US study which used data from CPS I in 1959 
(followed for 12 years) and CPS II in 1982 (followed for 18 years) found that men who reported 
current use of snuff or chewing tobacco had higher all-cause, coronary heart disease and stroke 
mortality compared to men that were non users in both CPS I and II; however current use of 
chewing tobacco or snuff at baseline was associated with higher risk for lung cancer and total 
cancer mortality only in CPS II and with higher risk for death from respiratory diseases only in 
CPS I and former use of snuff or chewing tobacco was not associated with any endpoint in CPS 
II (data on former use not available in CPS I).10 The study in CPS I and CPS II was restricted to 
men and additionally participants were older (mean age around 60 years at enrollment) than the 
age distribution of participants in this study (around 45 years at interview) and the study with 
TUS-CPS data (median within 35-49 years at baseline). Also, contrary to our data, current 
exclusive SLT users for CPS I and both current and former exclusive SLT users for CPS II were 
older than the never users.  
For cancer mortality, we found a non-significant modest increase in cancer mortality for current 
SLT users and no difference for former SLT users compared to never tobacco users. In the TUS-
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CPS study, cancer mortality for both exclusive current and former SLT was similar to never 
tobacco users (HR [95% CI] was 1.01 [0.73, 1.39] for former SLT users and 0.99 [0.82, 1.21] for 
current SLT users compared to never tobacco users).11 Several US and international studies have 
found that SLT users had higher risk in head and neck cancer (HNC) including oral cancer 
compared to never tobacco users,18-20, however only two studies9,18 examined mortality and they 
included few exclusive SLT users with cancer mortality not significantly associated with SLT 
use from these studies. Beside the relatively few exclusive SLT users, oral cancer which is 
associated with SLT use, is rare (3% of all cancer incidence) in the US21 and the five-year 
survival rate for oral cancer is 64.8%.21 This may lead to fewer observed events for a common 
cancer mortality outcome for exclusive SLT users and insufficient statistical power to detect the 
difference in total cancer mortality.  
For cardiovascular disease mortality, the current SLT users had significant lower mortality 
compared to never tobacco users while former SLT users had a similar mortality as never users. 
Our findings differ from previous studies which have found higher CVD mortality associated 
with SLT use compared to non-tobacco users.10,22,23 Our results were also consistent in analyses 
comparing risk for coronary heart disease and stroke mortality as separate endpoints (data not 
shown). In the study using data from Tobacco Use Supplement of Current Population Survey, 
there was significantly higher mortality from coronary heart disease but no difference in 
mortality from cerebrovascular disease for current exclusive SLT users compared to never 
tobacco users.11 
In this study, CLRD mortality did not differ for exclusive SLT users compared to never tobacco 
users which differs partially from findings from CPS I and CPS II which found higher 
respiratory mortality for men who were current exclusive smokeless tobacco in CPS I (1959–
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1972) but no difference in CPS II (1982–2000).10 In our study there were very few deaths from 
CLRD for SLT users (1 for Former SLT Users and 3 for Current SLT which may have limited 
our ability to examine risk for death from CLRD in our study compared to CPS.)   
Mortality Outcomes among Current Dual Users of Combustible and Smokeless Tobacco 
Products  
 
In this study, current dual users of combustible and smokeless tobacco products had higher risk 
for all-cause, cancer, CVD and CLRD mortality compared to never users; although findings were 
not statistically significant for CVD mortality. Furthermore, Current Dual Users had higher 
mortality than Current SLT Users but lower mortality than Current Smokers for all endpoints 
except for CLRD mortality for which Current Dual Users had higher mortality risk. Compared to 
Current Smokers, a larger proportion of Current Dual Users smoked cigars or pipes (17% vs. 
5%) in this study. A study in the Multi-Ethnic Study of Atherosclerosis found that cigar and pipe 
smoking was associated with decreased lung function and higher odds of airflow obstruction.26 
Additionally, although the average cigarettes smoked per day was similar between Current Dual 
Users and Current Smokers in this study, Current Dual Users were less likely to smoke cigarettes 
everyday than Current Smokers (65% vs. 78%). This finding suggests that some cigarette 
smokers may have reduced their frequency of smoking cigarettes by using smokeless tobacco 
products and subsequently lower their mortality risk compared to those who only smoke 
cigarettes and/or other combustible tobacco products. Indeed, in a study using data from 8,562 
adults who participated in NHIS 2010 showed higher odds of successful cigarette smoking 
cessation among SLT users (n=894) than those smokers who did not use SLT (n=7668).25  




The major strength of this study is the use of national representative survey information for US 
adults. The combined dataset from years 1987, 1992, 1998, 2000, and 2005 surveys yielded a 
large sample size which gave sufficient power to detect differences for several major causes of 
mortality between former and current exclusive smokeless tobacco users and former and current 
combustible smokers as well as dual users of these products. The availability of information on 
smokeless as well as cigarette and non-cigarette combustible tobacco products allowed us to 
compare risk for mortality to never users of these products. Information was available on both 
former and current use of these products which allowed use to evaluate the impact of quitting of 
these products on mortality outcomes. Follow-up for mortality endpoints were relatively long 
with a median follow-up time of more than 10 years. This study has some limitations, however. 
As the surveys had spanned across almost 20 years, the tobacco products used may have 
changed. In NHIS 2000 and 2005 information on bidis smoking was also included in the 
questionnaire. In a sensitivity analysis, including bidi smoking as a combustible tobacco product 
in defining tobacco use status, results were similar. Additionally, we included the survey year as 
a covariate in the model to account for potential secular trends.  Another limitation is the cross-
sectional nature of the NHIS survey data. Tobacco use could change over time and the 
classification of tobacco use behavior at baseline may not reflect the etiologically relevant 
exposure period. In this study, dual combustible and smokeless tobacco users who had quit SLT 
use or smoking by baseline were excluded as information on timing of quitting for SLT (needed 
to assess the order of quitting) was unavailable, therefore we were unable to examine mortality 
risk for these individuals. A study using CPS II data showed higher cancer mortality for SLT 
users who were former cigarette smokers compared to former cigarette smokers who quit using 
tobacco entirely.17 Lastly, this study examined risk for mortality outcomes and there was no 
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ascertainment for incidence of tobacco related diseases like cancer, CVD and respiratory 
outcomes. Diseases associated with smokeless tobacco use like oral cancer18-20 may not be the 
eventual cause of death but could greatly impact the quality of life for these tobacco users. 
Additional research evaluating the potential risk for these morbidity outcomes will lead to better 
understanding of public health implications of smokeless tobacco use.  
Conclusion 
 
Compared to combustible tobacco smoking, smokeless tobacco use was associated with lower 
risk of all-cause, cancer, CVD and chronical lower respiratory mortality. These results suggest 
that using smokeless tobacco as a replacement for combustible tobacco smoking may reduce 
mortality for adults with a history of smoking. Further prospective studies about smokeless 
tobacco risk compared to never tobacco users are needed. Before there is a definitive conclusion 
about the potential hazard with smokeless tobacco, no smokeless tobacco initiation should be 
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Table 1. Participant characteristics by tobacco use 
 Overall Never Users Former SLT Users Current SLT Users Former Smokers Current Smokers Current Dual Users 
N 127,995 65,447 888 1,100 27,351 32,150 1,059 
Age (year) 45.9 (0.1) 44.4 (0.1) 36.7 (0.5) 39.3 (0.6) 54.2 (0.1) 42.4 (0.1) 37.2 (0.5) 
Sex        
Female 75,095 (57.4%) 43,649 (64.9%) 115 (10.7%) 221 (14.9%) 13,711 (50.3%) 17,352 (53.0%) 47 (3.5%) 
Race/Ethnicity        
Non-Hispanic White 89,485 (75.5%) 42,248 (70.7%) 727 (85.8%) 865 (84.6%) 21,540 (83.4%) 23,188 (77.4%) 917 (89.1%) 
Non-Hispanic Black 17,304 (11.5%) 9,599 (13.0%) 83 (7.2%) 177 (10.6%) 2,562 (7.6%) 4,799 (12.3%) 84 (5.4%) 
Hispanic 17,121 (9.1%) 10,946 (11.4%) 60 (4.9%) 32 (2.0%) 2,654 (6.5%) 3,391 (7.4%) 38 (2.7%) 
Other 4,085 (3.9%) 2,654 (5.0%) 18 (2.0%) 26 (2.7%) 595 (2.5%) 772 (2.9%) 20 (2.9%) 
Education        
<High School 26,499 (17.9%) 12,587 (16.0%) 139 (12.7%) 338 (25.7%) 5,325 (17.3%) 7,808 (22.0%) 302 (26.6%) 
High school  41,024 (31.3%) 19,187 (28.3%) 240 (25.0%) 345 (31.6%) 8,634 (31.1%) 12,216 (37.8%) 402 (38.0%) 
Some College 32,471 (26.8%) 16,766 (27.0%) 262 (30.5%) 260 (26.8%) 6,925 (26.5%) 8,020 (26.6%) 238 (24.2%) 
≥ College Degree 28,001 (23.9%) 16,907 (28.7%) 247 (31.8%) 157 (16.0%) 6,467 (25.0%) 4,106 (13.6%) 117 (11.2%) 
Marital Status       
Marrieda 68,769 (53.7%) 34,596 (52.9%) 464 (53.9%) 549 (51.8%) 16,620 (60.5%) 15,944 (49.4%) 596 (53.3%) 
Poverty Level      
PIR<1 19,006 (13.4%) 9,979 (13.6%) 124 (12.2%) 239 (19.1%) 2,607 (8.6%) 5,894 (17.0%) 163 (16.0%) 
BMI (kg/m2) 27.0 (0.1) 26.9 (0.1) 26.9 (0.2) 28.0 (0.7) 27.8 (0.2) 26.5 (0.2) 26.5 (0.2) 
Cigarettes/dayb      16.6 (0.1) 17.4 (0.5) 
NHIS Survey Year        
1987  36,543 (20.5%)  17,130 (18.8%)     257 (19.4%)     357 (21.4%)   7,612 (19.7%)  10,783 (24.5%)     404 (25.3%) 
1992  10,009 ( 5.9%)   4,878 ( 5.6%)      79 ( 7.0%)     101 ( 6.5%)   2,205 ( 6.0%)   2,666 ( 6.4%)      80 ( 5.6%) 
1998  27,937 (24.2%)  14,386 (24.0%)     262 (33.4%)     230 (25.0%)   6,128 (24.6%)   6,705 (23.8%)     226 (25.9%) 
2000  27,721 (24.2%)  14,761 (24.5%)     132 (18.1%)     229 (24.8%)   5,910 (24.5%)   6,527 (23.4%)     162 (20.1%) 
2005  25,785 (25.2%)  14,321 (27.1%)     159 (22.1%)     183 (22.2%)   5,473 (25.1%)   5,463 (21.9%)     186 (23.1%) 
Abbreviations: PIR, Poverty-Income Ratio; BMI, body mass index; Values represent mean(SD) for continuous variables and N (weighted %) for 
categorical variables. 
a. Married: married with or without spouse living together or lived together with partner 
b. Cigarettes/day information was only available for current cigarette smokers (N= 30,609 for Current Smokers and N=911 for Current Dual Users with 




Table 2. Hazard ratio (95% CI) for mortality outcomes by tobacco use 
 N 
All-cause mortality Cancer mortality CVD mortality CLRD mortality 
# of 
deaths 
HR (95% CI) 
# of 
deaths 
HR  (95% CI) 
# of 
deaths 
HR  (95% CI) 
# of 
deaths 
HR  (95% CI) 
Never Users 65,447 9,316 1.00 (ref) 1,785 1.00 (ref) 2,962 1.00 (ref) 174 1.00 (ref) 
Former SLT 
Users 
888 100 0.93 (0.76-1.14) 17 0.71 (0.41-1.22) 34 0.84 (0.60-1.16) 1 0.53 (0.07-3.85) 
Current SLT 
Users 
1,100 202 0.95 (0.80-1.12) 44 1.15 (0.80-1.63) 56 0.70 (0.53-0.93) 3 1.04 (0.33-3.29) 
Former 
Smokers 
27,351 7,094 1.29 (1.25-1.34) 1,662 1.53 (1.42-1.64) 2,003 1.10 (1.03-1.17) 513 5.25 (4.28-6.45) 
Current 
Smokers 
32,150 6,478 1.85 (1.78-1.93) 1,965 2.73 (2.52-2.95) 1,600 1.56 (1.45-1.68) 585 10.08 (8.17-12.43) 
Current Dual 
Users 
1,059 215 1.69 (1.48-1.94) 51 2.03 (1.52-2.71) 52 1.27 (0.94-1.72) 21 12.12 (7.57-19.41) 
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; CLRD, chronic lower respiratory disease; HR, hazard ratio 
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